REGN FY 2024 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14.2B+8.3% YoY

Gross Profit

$12.2B86.1% margin

Operating Income

$4.0B28.1% margin

Net Income

$4.4B31.1% margin

EPS (Diluted)

$38.34

Cash Flow

Operating Cash Flow

$4.4B

Free Cash Flow

$3.7B

Stock-Based Comp.

$983M

Balance Sheet

Total Assets

$37.8B

Total Liabilities

$8.4B

Stockholders' Equity

$29.4B

Cash & Equivalents

$2.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14.2B	$13.1B	+8.3%
Gross Profit	$12.2B	$10.9B	+12.5%
Operating Income	$4.0B	$4.3B	-8.2%
Net Income	$4.4B	$4.0B	+11.6%